17:40 , Dec 11, 2018 |  BC Innovations  |  Translation in Brief

Diseased oligodendrocytes

A Karolinska Institute team has identified subsets of oligodendrocyte lineage cells that may trigger T cell immunity in multiple sclerosis and proposed the cells as new disease targets. The findings suggest the myelin-producing cells are...
03:55 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Filaments line up as MS biomarker

Neurofilament assays appear on track to become the biomarker of choice for a wide range of neurodegeneration studies, given their tight correlation with axon damage and detectability in blood. If prospective trials can reinforce the...
20:02 , Nov 2, 2018 |  BC Week In Review  |  Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
15:33 , Nov 1, 2018 |  BC Extra  |  Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); Alzheimer’s disease (AD) Mouse studies suggest a mAb against fibrin could help treat MS and AD. In a mouse model of chronic MS and two mouse models of relapsing-remitting MS (RRMS),...
00:40 , Oct 19, 2018 |  BC Innovations  |  Emerging Company Profile

Altheia: Proliferating PD-L1

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis. Altheia...
21:19 , Oct 15, 2018 |  BC Extra  |  Preclinical News

mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's

Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune CNS diseases such as multiple sclerosis or Alzheimer's disease by specifically blocking the proinflammatory effects of fibrin without compromising its clotting ability....
17:34 , Oct 15, 2018 |  BC Extra  |  Company News

New CEO Forster eyes capital raise for F-star

Immuno-oncology company F-star Biotechnology Ltd. (Cambridge, U.K.) named Eliot Forster as CEO, replacing John Haurum. Forster was CEO of Oxford-based TCR biologics play Immunocore Ltd. (Abingdon, U.K.), which he left in February. Since becoming CEO...
18:10 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
17:34 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

FDA, EMA to review Novartis' siponimod for secondary progressive MS

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA and MAA have accepted applications for siponimod (BAF312) to treat secondary progressive multiple sclerosis (SPMS). The PDUFA date for the NDA is in March 2019; Novartis expects a decision...